- Max Financial’s net income for the second quarter was 41.2 million rupees, a significant decrease of 96% compared to the previous year.
- This net income figure missed the analyst estimate of 1.14 billion rupees by a wide margin.
- The company’s revenue totaled 97.9 billion rupees, which is down 27% year-over-year.
- This revenue result, however, exceeded the estimated figure of 46.19 billion rupees.
- Total costs for the company remained at 97.9 billion rupees, reflecting a 26% decrease from the previous year.
- Analyst sentiment remains positive, with 24 buy ratings, 2 hold ratings, and no sell ratings.
A look at Max India Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Max India Ltd, operating as a life insurance company, is positioned for a positive long-term outlook based on the Smartkarma Smart Scores analysis. With a growth score of 3, the company shows promise for expansion and development in the future. Additionally, scoring a resilience score of 3 suggests that Max India Ltd has the ability to withstand market challenges and maintain stability. Momentum, scoring a solid 4, indicates strong market momentum and investor interest in the company.
Although the company has room for improvement in the value and dividend categories with scores of 2 and 1 respectively, its overall outlook remains optimistic. Max India Ltd, a player in the insurance and health industry, is poised to leverage its strengths in growth, resilience, and momentum to drive long-term success in the market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
